Silo Pharma Inc. (SILO), a developmental-stage biopharmaceutical company, on Monday announced plans to advance psychedelic-based therapies for treating mental health disorders, including SPC-15 in treating post-traumatic stress disorder, following an executive order by the U.S. government.
The executive order was issued on April 18, 2026, and directs multiple U.S. government agencies to accelerate research into psychedelic therapies and patient access to mental health treatments. Silo's lead program, SPC-15, is a novel serotonin 4 (5-HT4) receptor agonist formulated as an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). The nose-to brain administration system allows for rapid delivery to the central nervous system (CNS). The SPC-15 program is being advanced under a 505(b)(2) regulatory pathway, to enable a streamlined development timeline.
The company anticipates filing an investigational new drug (IND) application for SPC-15 with the U.S. Food and Drug Administration (FDA).
SILO closed Friday at $0.51, up 1.18%. In the premarket, shares are trading at $0.52, up 0.95%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.